About: Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant
Creator	Andersson, M Andersson, • Lunell, E Molander, ) Molander, •
Source	PMC
abstract	The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state. Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of C(max), AUC and t(max) were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the t(max) ratio to 1.72. The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.
has issue date	1995-01-01(xsd:dateTime)
bibo:doi	10.1007/bf00202176
bibo:pmid	7542589
has license	no-cc
sha1sum (hex)	268a89879b470523856211ef78dd1e375f7a48e6
schema:url	https://doi.org/10.1007/bf00202176
resource representing a document's title	Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant
has PubMed Central identifier	PMC7087527
has PubMed identifier	7542589
schema:publication	Eur J Clin Pharmacol
resource representing a document's body	covid:268a89879b470523856211ef78dd1e375f7a48e6#body_text
is schema:about of	named entity 'RELATIVE BIOAVAILABILITY' named entity 'ORDER' named entity 'PATIENTS' named entity 'XYLOMETAZOLINE' named entity 'GENERALLY' named entity 'SUFFERING' named entity 'RHINITIS' covid:arg/268a89879b470523856211ef78dd1e375f7a48e6 named entity 'USE OF' named entity 'MEASUREMENTS' named entity 'CONTROL' named entity 'NICOTINE' named entity 'DECONGESTANT' named entity 'A COMMON' named entity 'NICOTINE' named entity 'CONCURRENT' named entity 'SMOKERS' named entity 'ADMINISTRATION' named entity 'INFECTIOUS RHINITIS' named entity 'NASAL SPRAY' named entity 'STATE' named entity 'RELATIVE BIOAVAILABILITY' named entity 'SESSION' named entity 'NASAL SPRAY' named entity 'NASAL VASOCONSTRICTOR' named entity 'ACCEPTED' named entity 'DOSE' named entity 'DISEASE-FREE' named entity 'COMMON COLD' named entity 'DECONGESTANT' named entity 'GIVEN' named entity 'TOPICAL' named entity 'CRITERIA' named entity 'ACCORDING' named entity 'SINGLE' named entity 'ASSESSED' named entity 'bioavailability' named entity 'concurrent administration' named entity 'xylometazoline' named entity 'topical decongestant' named entity 'bioequivalence' named entity 'blood samples' named entity 'common cold' named entity 'cough' named entity 'nicotine patch' named entity 'AUC' named entity 'plasma' named entity 'plasma' named entity 'rhinitis' named entity 'xylometazoline' named entity 'disease-free' named entity 'nicotine' named entity 'ANOVA' named entity 'nicotine' named entity 'common cold' named entity 'airway' named entity 'nasal obstruction' named entity 'inflammatory diseases' named entity 'intranasally' named entity 'disease-free' named entity 'elimination half-life' named entity 'rhinitis' named entity 'decongestant' named entity 'xylometazoline' named entity 'rhinitis' named entity 'decongestant' named entity '0.98' named entity 'disease-free' named entity 'nasal discharge' named entity 'disease-free' named entity 'maximum plasma concentration' named entity 'common cold' named entity 'nicotine' named entity 'therapeutic range' named entity 'plasma' named entity 'nasal vestibule' named entity 'Oral contraceptives'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software